MedTrace Logo

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

NCT07036003 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-03-16

No results posted yet for this study

Summary

The goal of this clinical trial is to see if people with knee osteoarthritis would be willing to comply and adhere to incorporating Recombinant Human Growth Hormone (rHGH), specifically Saizen Somatropin solution, into their treatment plan.

Participants will be asked to:

* Self-inject the treatment solution (placebo or somatropin) into the abdominal or gluteal area once per day for a total of 6 weeks.
* Complete questionnaires related to their knee pain and activities of daily living.
* Provide blood tests.
* Complete various measurements including: circumference of thigh, calf, and abdomen; strength of thigh and knee; range of motion of both knees; and gait analysis.

Conditions

  • Knee Osteoarthritis (Knee OA)
  • Knee Osteoarthritis (OA)

Interventions

DRUG

Somatropin (recombinant human growth hormone)

Study participants will deliver Somatropin via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks at a dose of 0.5mg/day per body surface area (0.5mg/m2/day).

DRUG

bacteriostatic saline placebo

Study participants will deliver bacteriostatic saline via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks in an identical delivery device to the experimental arm.

Sponsors & Collaborators

  • Sunnybrook Research Institute

    collaborator OTHER

  • Dr. David Wasserstein

    lead OTHER

Principal Investigators

  • Dr. David Wasserstein · Sunnybrook Health Sciences Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2028-07-31
Completion
2029-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07036003 on ClinicalTrials.gov